Clinical trial · Observational
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
NCT05556486CI-TRIAL-00061064CeNo2unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study investigates the occurance of GlioStem positive tumor stem cells in the rescection marigins of hig grade human gliomas
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma, Malignant | Malignant Glioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GlioStem | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- GlioStem frequency
- timeFrame
- May 2025
- description
- Frequency of GlioStem positive tumor cells in marigin of tumor compared to outside resection marigin.
Secondary outcomes (1)
- measure
- GlioStem genetic
- timeFrame
- May 2025
- description
- Characterization of molecular genetic alterations in GlioStem psoitive cells in tumor compared to outsid resection marigin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Operation for high grade malignat glioma (novel or recurrence) Exclusion Criteria: * Unable to provide informed consent * Insufficent tissue material to allow GlioStem analysis while not compromising histopathological analysis.
References
Publications (0)
Data not yet available
No reference posted for this study.